Related Experiment Videos
Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study
Takashi Togo1, Katsuo Kojima, Mika Shoji
1Department of Psychiatry, Yokohama Maioka Hospital, Yokohama, Japan. togo-t@rd6.so-net.ne.jp
International Clinical Psychopharmacology
|April 23, 2004
Summary
Schizophrenia patients on olanzapine or risperidone showed higher adiponectin levels than healthy individuals. This suggests adiponectin may help normalize metabolic changes during antipsychotic treatment.
Area of Science:
- Endocrinology
- Psychiatry
- Metabolic Research
Background:
- Adiponectin, an adipocyte-derived protein, influences glucose metabolism, insulin sensitivity, and adiposity.
- Antipsychotic medications like olanzapine and risperidone can impact metabolic parameters in schizophrenia patients.
Purpose of the Study:
- To investigate changes in serum adiponectin concentrations in schizophrenia patients treated with olanzapine or risperidone.
- To compare adiponectin levels between patients and healthy controls, considering body mass index (BMI) and age.
Main Methods:
- Serum adiponectin levels were measured in three groups: schizophrenia patients on olanzapine (n=18), on risperidone (n=15), and healthy volunteers (n=17).
- Participants were age- and BMI-matched. Patients had stable doses for at least 4 weeks.
Main Results:
- Patients treated with olanzapine or risperidone exhibited significantly higher serum adiponectin concentrations compared to healthy volunteers, independent of BMI.
- In olanzapine-treated patients, adiponectin levels decreased with increasing BMI.
- In risperidone-treated patients, elevated adiponectin levels were observed irrespective of adiposity.
Conclusions:
- Adiponectin appears to play a role in regulating glucose metabolism and weight in schizophrenia patients undergoing olanzapine or risperidone treatment.
- Elevated adiponectin may indicate a normalizing effect on metabolic abnormalities associated with these antipsychotic medications.